Stoke Therapeutics
在场
高管
查看带有其 19 名主要高管的组织结构图
Stoke Therapeutics 搜索最多的简介
- Edward Kaye, Chief Executive Officer and Director
- Arthur Levin, Director
- Jennifer Burstein, Director
高管在Stoke Therapeutics变化
- Eric Olson已作为Chief Business Officer加入公司 (新闻发布的2024九月5号).
- Stephen Tulipano, Chief Financial Officer, 已经离开公司 (新闻发布的2024四月30号).
- Thomas Leggett已作为Chief Financial Officer加入公司 (新闻发布的2024四月30号).
创建提醒
跟踪 Stoke Therapeutics 的高管变动
生物技术
Stoke Therapeutics 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Stoke Therapeutics 的最新新闻稿
- Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates - Stoke Therapeutics
- Press Releases - Stoke Therapeutics
- Press Releases - Stoke Therapeutics
- Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference - Stoke Therapeutics
- Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome - Stoke Therapeut
- Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome - Stoke
- Press Releases - Stoke Therapeutics
- Press Releases - Stoke Therapeutics
- Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome - Stoke Therapeutics
- Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference - Stoke Therapeutics
- View more press releases Close
通过电子邮件
